Aspen Aerogels lowers FY15 GAAP EPS view to (30c)-(26c) from (25c)-(20c) Narrows FY15 revenue view to $118M-$120M from $118M-$122M. Consensus is for FY15 EPS (26c) and for revenue $120.40M. Changes in outlook are the result of the CO2 supply disruption. Sees FY15 adjusted EBITDA $8.2M-$9.5M, down from the prior guidance range of $9.2M-$10.6M. Aspen Aerogels' 2015 outlook assumes depreciation and amortization expense of $9.7M-$9.9M, stock based compensation expense of between $5.3M-$5.4M, interest expense of $200,000, and weighted-average shares of common stock outstanding of approximately 23M for the full year. Aspen Aerogels' 2015 outlook also assumes that supply of Aspen Aerogels' full daily CO2 requirement will resume by October 1. While there can be no assurance by Aspen Aerogels that supply of its daily CO2 requirement will be met in full by October 1 Aspen Aerogels currently does not anticipate updating guidance further prior to its press release reporting financial results for the Q3.